BridgeMD
GSDIa Disease Monitoring Program
EU CTIS ID: 2023-510219-20-00
What this study is testing
Evaluate the long-term safety and pregnancy outcomes of DTX401 in patients with GSDIa
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient who had • DTX401 (full or partial dose) administered in a parent clinical study (Group 1) or • Prescribed DTX401 (full or partial dose) administered in a post-marketing setting (Group 2)
- Patient is willing and able to provide informed consent after the study has been explained, and prior to any research-related assessments or procedures. If a minor or an adult with cognitive limitations, the patient is willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures.
You likely can't join if
- Presence of any condition that would interfere with study participation, interpretation of results or affect patient’s safety in the opinion of the Investigator
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Brazil
- Canada
- United States
- South Africa
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Brazil; Canada; United States; South Africa. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.